Table 4.

Results of Cox proportional hazards model for therapy discontinuation

	Study population (N = 48,212)
Variable	Hazards ratio	p-value
Age	0.989	<.0001*
Female	1.048	0.0002*
RxRisk categoriesa
Anxiety and Tension, Bipolar Disorder, Depression, Psychotic Illness, ADD	1.079	<.0001*
Asthma, Allergic Rhinitis	1.031	0.1891
Cardiac Disease, Coronary & Peripheral Vascular Disease, Heart Disease, Hypertensionb	0.973	0.2432
Gastric acid disorder, IBS	1.004	0.8477
Rheumatoid Arthritis, Gout	1.147	<.0001*
Thyroid Disease	0.951	0.0426*
Diabetes	1.158	<.0001*
Business Type
HMO	N/A	N/A
Medicaid	1.339	<.0001*
Medicare	1.451	<.0001*
Self	1.056	0.0013*
Concomitant Other CVD-related Medications Used
Digitalis	1.138	0.0086*
Nitrates	1.224	<.0001*
Antiplatelet Medications	1.097	0.0502
Antihyperlipidemic Medications	0.797	<.0001*
Average copayc	1.001	0.3831
Target medication classesd
ARB/HCTZ	0.529	<.0001*
ACEI/HCTZ	0.536	<.0001*
BB/HCTZ	0.532	<.0001*

* Significant p-value

^a RxRisk categories shown in this table include the 7 most frequent disease states in the study cohort. All RxRisk disease categories were included in the model.

^b This RxRisk category does not include the target medications, digitalis, nitrates, antiplatelet medications or antihyperlipidemics.

^c Limited to HTN medications of the same class as the index drug.

^d Reference Medication Class = HCTZ